Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | MASP2 | O00187 | 1/20 | 0.63 |
| ▸ | ABCC1 | P33527 | 6/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3353110 | 0.84 | KDM4E (0.66) | KDM4EALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL10827700 | 0.83 | LMNA (0.72) | KDM4EALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL31212658 | 0.82 | CA1 (0.71) | KDM4EALDH1A1POLBKMT2AMASP2 | |
| SCHEMBL5455412 | 0.82 | CA1 (0.71) | KDM4EALDH1A1POLBKMT2AMASP2 | |
| SCHEMBL8686791 | 0.81 | ALDH1A1 (0.70) | KDM4EALDH1A1POLBKMT2AMASP2 | |
| SCHEMBL14906959 | 0.81 | MASP2 (0.67) | KDM4EALDH1A1POLBKMT2AMASP2 | |
| SCHEMBL742429 | 0.79 | NPSR1 (0.67) | KDM4EALDH1A1POLBKMT2AMASP2 | |
| SCHEMBL11681834 | 0.79 | ALDH1A1 (0.59) | KDM4EALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL3627546 | 0.78 | MASP2 (0.62) | KDM4EALDH1A1POLBKMT2AMASP2 | |
| SCHEMBL25054195 | 0.77 | MASP2 (1.00) | KDM4EALDH1A1POLBKMT2AMASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12173185-B1 | Selenated thiourea-based hybrid compounds as corrosion inhibitors for steel pipelines | King Faisal University (SA) | 2024-12-24 | — | — | US | claimed |
| US-20080161325-A1 | e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome | ELAN PHARMACEUTICALS, INC. | 2008-07-03 | — | — | US | claimed |
| EP-1534693-A2 | 1, 3-DIAMINO-2-HYDROXYPROPANE PRODRUG DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2005-06-01 | — | — | EP | claimed |
| WO-2004022523-A2 | 1, 3-DIAMINO-2-HYDROXYPROPANE PRODRUG DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2004-03-18 | — | — | WO | claimed |
| US-20080161325-A1 | e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome | ELAN PHARMACEUTICALS, INC. | 2008-07-03 | — | — | US | disclosed |
| US-7294642-B2 | 1,3-Diamino-2-hydroxypropane pro-drug derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12173185-B1 | Selenated thiourea-based hybrid compounds as corrosion inhibitors for steel pipelines | TST, SCLY, SELENOI | KDM4E 3986/4885ALDH1A1 2213/4885POLB 324/4885 |
| US-20080161325-A1 | e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome | BACE1, APP, BACE2 | KDM4E 3054/4885ALDH1A1 2178/4885POLB 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.